Anti-CD47 Antibodies (with Tioma)
Oncology
Pre-clinicalActive
Key Facts
About GlobalBio
GlobalBio is a private, pre-revenue biotech firm specializing in antibody discovery and engineering. Its core assets are the ALTHEA Gold Libraries™ platform for therapeutic antibody discovery and a proprietary humanization technology (GBM-Humanization™). The company operates through collaborations with pharmaceutical partners like Janssen and Tioma Therapeutics, positioning itself as a technology and service provider in the competitive antibody therapeutics space. Its strategic focus is on oncology, with early-stage programs targeting CD47.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |